newsCOVID-19 and multiple sclerosis patients experienced reduced inflammation when given…
9 March 2023 | By Catherine Eckford (European Pharmaceutical Review)
COVID-19 and multiple sclerosis patients experienced reduced inflammation when given the first nasal monoclonal antibody in a pilot trial.